Pacira BioSciences Inc. (PCRX) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-03, Pacira BioSciences Inc. (NASDAQ: PCRX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $36.40 (+0.03% 1D, market cap $1.45B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, PCRX ranks #119 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCRX carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of 79.4%, and ROIC of 1.7%. By comparison, TYRA (Tyra Biosciences Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $1.45B) and GHRS (GH Research PLC) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.43B). Among the 5-stock peer group, PCRX leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).
Per PCRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001396814), Pacira BioSciences Inc. generated $726.4M in revenue (+3.6% YoY), $7.0M in net income, and $136.7M in free cash flow against $1.26B in total assets and $372.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±1.8% realized swing band)
Altman Z-Score 2.33 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 8/9
Capital intensity & 2.6% operating margin leave 12 pts on the table
Even with a 65/100 (C) score, PCRX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 76.9% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($29.53) or 200D SMA ($25.01) invalidates the momentum regime and cuts Target Base ($37.55) toward Bear Floor ($29.29).
Pacira BioSciences Inc. (PCRX) advanced +0.03% to $36.40, trading at 98% of its 52-week range ($18.8 – $36.67). Solid 79.4% gross margin (2% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Viatris report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
The Motley Fool report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Morningstar report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Reuters report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to purchase all of the
Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +3.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PCRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PCRX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Pacira BioSciences Inc. (PCRX) ranks #119 by composite RQD confidence (65/100, grade C) and #304 by equity capitalization ($1.45B). Within this direct 5-issuer industry benchmark cohort, PCRX leads on earnings valuation at N/A trailing P/E, while ANAB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. PCRX currently leads its immediate peer cohort in composite quantitative strength at 65/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PCRX
ACTIVE
Pacira BioSciences Inc. | C | 65/100 | — | 79.4% | 1.7% | +0.03% | $1.45B | Benchmark Subject |
| TYRA Tyra Biosciences Inc. | E | 30/100 | — | — | -35.0% | +1.23% | $1.45B | /tyra-vs-pcrx → |
| GHRS GH Research PLC | D | 49/100 | — | — | — | -1.73% | $1.43B | /ghrs-vs-pcrx → |
| ANAB AnaptysBio Inc. | C- | 60/100 | — | — | 85.0% | -2.84% | $1.43B | /anab-vs-pcrx → |
| ETON Eton Pharmaceuticals Inc. | D+ | 57/100 | — | 53.5% | -0.9% | -2.63% | $1.49B | /eton-vs-pcrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pacira BioSciences Inc. (PCRX) reported GAAP revenue of $726.4M (+3.6% vs. FY2024 revenue of $701.0M , and +7.6% cumulative change since FY2023) , GAAP net income of $7.0M, operating cash flow of $152.0M, and free cash flow of $136.7M (-23.5% YoY). On the balance sheet, PCRX closed FY2025 with $1.26B in total assets against $372.2M in total debt (Altman Z-Score: 2.33, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $726.4M | $7.0M | $152.0M | $136.7M | $1.26B | $372.2M |
| FY2024 (FY) | 2024-12-31 | $701.0M | -$99.6M | $189.4M | $178.8M | $1.55B | $383.5M |
| FY2023 (FY) | 2023-12-31 | $675.0M | $42.0M | $154.6M | $154.6M | — | — |
As of 2026-11-03, Pacira BioSciences Inc. (NASDAQ: PCRX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $36.40 (+0.03% 1D, market cap $1.45B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, PCRX ranks #119 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCRX carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of 79.4%, and ROIC of 1.7%. By comparison, TYRA (Tyra Biosciences Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $1.45B) and GHRS (GH Research PLC) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.43B). Among the 5-stock peer group, PCRX leads on earnings multiple (N/A) while ANAB leads on capital efficiency (85.0% ROIC).
Per PCRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001396814), Pacira BioSciences Inc. generated $726.4M in revenue (+3.6% YoY), $7.0M in net income, and $136.7M in free cash flow against $1.26B in total assets and $372.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
PCRX last traded at $36.40 (+0.03% on volume of 810,961 shares), positioning the stock +23.26% above its 50-day simple moving average ($29.53) and +45.54% above its 200-day simple moving average ($25.01). Across its 52-week range of $18.80 to $36.67, PCRX sits at the 98.5% percentile with a 14-day RSI of 83.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±1.8% ($35.74 to $37.06).
Pacira BioSciences Inc. (PCRX) earns a live Roarable RQD composite score of 65/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $36.40 (+0.03% 1D, market capitalization $1.45B).
Pacira BioSciences Inc. (PCRX) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Per the recent news wire, Viatris has agreed to acquire Pacira, with the framing centered on non-opioid pain therapies.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Pacira BioSciences Inc. (PCRX) reported $726.4M in annual revenue (up from $701.0M in FY2024, +3.6% YoY) and $7.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($675.0M revenue, $42.0M net income) through FY2025, PCRX scaled operating cash flow to $152.0M and free cash flow to $136.7M, backed by $1.26B in total assets against $372.2M in total debt.
An investor should note that the pending acquisition itself is the dominant event in the news flow; how it affects counterparties and sector peers is not resolved by the data.
Real-time company headlines, analyst actions, and sector developments for Pacira BioSciences Inc. (PCRX) • Click "Debate This Headline" to argue it in the Roar Pit below
Viatris report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
The Motley Fool report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Morningstar report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Reuters report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Pacira BioSciences Inc. (PCRX) market action, institutional positioning, and fundamental catalysts.
The street is overcomplicating Pacira BioSciences Inc. (PCRX). Institutional positioning (16/20 whale flow) and a Piotroski F-Score of 8/9 point to a financially sound, institutionally supported profile amid a reported Viatris acquisition.. With an RQD score of 65/100 (C) and Forensic Balance Sheet at 14/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $39.30.
@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (79.4%) holds, EPS grows into the multiple faster than bears think.
Sitting on the sidelines or leaning short PCRX above $36.39. ROIC of 1.7% and an EV/EBITDA of 51.6 leave weak capital efficiency and rich valuation against an operating margin of only 2.6%.. Until Fundamental Cash Engine (8/20) and FCF yield (9.42%) inflect higher, upside is capped near $36.67.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: